The Best Small-Cap Stocks to Buy Now
Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
The final quarter of 2025 and first quarter of the new year could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps have underperformed during the current bull market. After all, small caps as an asset class have been a dud. They've struggled to keep up as mega-cap stocks pushed the broader market to record highs.
To recap: the broader S&P 500 is up more than 80% since the bull market's onset three years ago. The tech-heavy Nasdaq Composite more than doubled over the same span. Hurt partly by its price-weighted construction, the blue-chip Dow Jones Industrial Average gained just 55%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) have been fueling much of the market's gains. And so small caps – which tend to be more sensitive to the economic cycle, tariffs and interest rates – are lagging badly.
Indeed, the small-cap benchmark Russell 2000 Index is up just 41% over the past three years.
If there is a sliver of a silver lining to the Russell 2000's chronic underperformance, it's that small cap valuations look dirt cheap.
"The broadening of profits growth is finally extending into small caps," notes Jill Carey Hall, an equity and quant strategist at BofA Securities. "Small caps continue to trade at about a 30% historical discount to large caps, implying likelihood of outperformance over the long-term. We remain constructive on small caps for now."
And with the Federal Reserve expected to enact several cuts to the federal funds rate in the coming quarters, small caps should have at least one catalyst behind them.
Our methodology for finding the best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.
Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.
Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.
That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Analysts' consensus recommendation score | Subsector | Analysts' consensus recommendation |
|---|---|---|---|
Spyre Therapeutics (SYRE) | 1.14 | Biotechnology | Strong Buy |
Denali Therapeutics (DNLI) | 1.16 | Biotechnology | Strong Buy |
Waystar Holding (WAY) | 1.19 | Health Care Technology | Strong Buy |
Xenon Pharmaceuticals (XENE) | 1.21 | Biotechnology | Strong Buy |
Genius Sports (GENI) | 1.22 | Casinos & Gaming | Strong Buy |
Janux Therapeutics (JANX) | 1.22 | Biotechnology | Strong Buy |
Axsome Therapeutics (AXSM) | 1.25 | Pharmaceuticals | Strong Buy |
Wave Life Sciences (WVE) | 1.27 | Pharmaceuticals | Strong Buy |
Kymera Therapeutics (KYMR) | 1.27 | Biotechnology | Strong Buy |
Riot Platforms (RIOT) | 1.28 | Application Software | Strong Buy |
Avidity Biosciences (RNA) | 1.28 | Biotechnology | Strong Buy |
Braze (BRZE) | 1.30 | Application Software | Strong Buy |
Biohaven (BHVN) | 1.33 | Biotechnology | Strong Buy |
Guardant Health (GH) | 1.35 | Health Care Services | Strong Buy |
BridgeBio Pharma (BBIO) | 1.37 | Biotechnology | Strong Buy |
Essential Properties Realty Trust (EPRT) | 1.37 | Diversified REITs | Strong Buy |
Arcellx (ACLX) | 1.39 | Biotechnology | Strong Buy |
Privia Health Group (PRVA) | 1.40 | Health Care Services | Strong Buy |
IDEAYA Biosciences (IDYA) | 1.42 | Biotechnology | Strong Buy |
NetSTREIT (NTST) | 1.50 | Retail REITs | Strong Buy |
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
Dow Hits New High Ahead of January Jobs Report: Stock Market TodayA weak reading on December retail sales was in focus ahead of Wednesday's delayed labor market data.
-
7 Bad Tax Habits to Kick Right NowTax Tips Ditch these seven common habits to sidestep IRS red flags for a smoother, faster 2026 income tax filing.
-
The New Plan to End Surprise Taxes on Social Security 'Back Pay'Social Security Taxes on Social Security benefits are stirring debate again, as recent changes could affect how some retirees file their returns this tax season.
-
Dow Hits New High Ahead of January Jobs Report: Stock Market TodayA weak reading on December retail sales was in focus ahead of Wednesday's delayed labor market data.
-
The Best Weekly Income ETFs to Buy in 2026Weekly income ETFs are among the yield-based products that fund issuers are rolling out, but complexity and fees still matter.
-
Tied Up in Knots Over a Concentrated Stock Position? This Strategy Will Help You UnravelIf you've built significant wealth through stock in one company, deciding your next move may be petrifying. Use this decision-making framework to get unstuck.
-
How to Put Your IRA to Work for Change and to Help the Next Generation, Courtesy of an Investment AdviserUnhappy with the environmental and social impact of your investments? An impact fund that aligns your portfolio with your values could make all the difference.
-
A Wake-Up Call and a Healthy Dose of Terror: How to Survive Your First Days in PrisonThis young man needed to be scared straight after his mother expressed her fear that he was on a path to prison. Hearing these eight do's and don'ts worked.
-
Tech Stocks Fuel Strong Start to the Week: Stock Market TodayThe blue-chip Dow Jones Industrial Average extended its run above 50,000 on Monday and there are plenty of catalysts to keep the 30-stock index climbing.
-
I'm a Financial Adviser: Here's How to Help Derisk Your Portfolio in 2026Signs of a possible economic slowdown call for balanced derisking that locks in portfolio gains without sacrificing future upside. Here's a step-by-step guide.
-
Why the Next Fed Chair Decision May Be the Most Consequential in DecadesKevin Warsh, Trump's Federal Reserve chair nominee, faces a delicate balancing act, both political and economic.